Treatment Options for Triple-class Refractory Multiple Myeloma
Author:
Funder
AbbVie
Celgene
Sanofi
Karyopharm Therapeutics
Publisher
Elsevier BV
Subject
Cancer Research,Oncology,Hematology
Reference61 articles.
1. Myeloma plasma cells alter the bone marrow microenvironment by stimulating the proliferation of mesenchymal stromal cells;Noll;Haematologica,2014
2. Management of newly diagnosed symptomatic multiple myeloma: updated Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) consensus guidelines 2013;Mikhael;Mayo Clin Proc,2013
3. From transplant to novel cellular therapies in multiple myeloma: European Myeloma Network guidelines and future perspectives;Gay;Haematologica,2018
4. Modern multiple myeloma therapy: deep, sustained treatment response and good clinical outcomes;Landgren;J Intern Med,2017
5. Multiple myeloma, version 3.2017, NCCN clinical practice guidelines in oncology;Kumar;J Natl Compr Canc Netw,2017
Cited by 85 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Nursing Considerations for the Clinical Management of Adverse Events Associated with Talquetamab in Patients with Relapsed or Refractory Multiple Myeloma;Seminars in Oncology Nursing;2024-10
2. The 5T's of health disparities in multiple myeloma in Latin America;Current Opinion in Oncology;2024-09-09
3. Matching-adjusted indirect comparison of talquetamab vs selinexor-dexamethasone and vs belantamab mafodotin in patients with relapsed/refractory multiple myeloma;Current Medical Research and Opinion;2024-09-03
4. Absolute Lymphocyte Count and Outcomes of Multiple Myeloma Patients Treated with Idecabtagene Vicleucel: The US Myeloma Immunotherapy Consortium Real- World Experience;Transplantation and Cellular Therapy;2024-08
5. ASTCT Committee on Practice Guidelines Survey on Evaluation and Management of Relapsed/Refractory Multiple Myeloma after Failure of Chimeric Antigen Receptor T Cell Therapy;Transplantation and Cellular Therapy;2024-08
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3